Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
CEO: Matthew E. Lipman. Company website
Capstone Holding Corp. (CAPS) trades at $0.23, down 27.16% on the day, as of Sep 20, 2026 14:59 UTC.
Capstone Holding Corp. has a market capitalisation of $1.25M, calculated from the live CAPS share price and shares outstanding.
CAPS has no meaningful price-to-earnings ratio: Capstone Holding Corp. lost $4.12 per share over the last twelve months, and a P/E is only defined on positive earnings.
Capstone Holding Corp. generated revenue of $46.88M over the trailing twelve months, which puts the stock at 0.03 times sales.
CAPS has traded between $0.21 and $0.89 over the past 52 weeks, and the last price is 74.1% below that high.
No. Capstone Holding Corp. is loss-making, with a net margin of -46.79% over the trailing twelve months.
Wall Street analysts rate CAPS Buy.
Capstone Holding Corp. is classified under the Basic Materials sector and the Construction Materials industry, and is domiciled in US .
Matthew E. Lipman is the chief executive of Capstone Holding Corp., which employs 36 people.
QFI Terminal shows CAPS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CAPS in Terminal See plans